Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Fresenius Kabi Contract Manufacturing is the contract manufacturing platform of Fresenius Kabi, providing partners access to the expertise of more than 20 manufacturing sites. We offer the full range of services for fill/finish of solutions and emulsions in ampoules, vials, bottles, IV-bags, and pre-filled syringes. Our manufacturing facilities are registered by all regulatory bodies worldwide.
The U.S. launch of Conexxence and Bomyntra follows the FDA’s approval in March 2025.
By: Rachel Klemovitch
Otulfi was approved in September 2024 by the FDA for both subcutaneous and intravenous formulations as a biosimilar to Stelara.
New algorithm increases plasma collection while maintaining donor safety.
By: Charlie Sternberg
Demonstrates its commitment to providing quality, cost-saving treatment options to clinicians and the patients they serve.
Integration of Ori's IRO Platform with Cue and Lovo processing systems aims to enhance efficiency in CGT manufacturing.
By: Kristin Brooks
Aim to integrate Fresenius Kabi’s suite of cell therapy processing technologies within Cellular Origins’ CGT robotic manufacturing platform Constellation.
Aim to provide cost-effective, high-quality biosimilar treatments that address critical unmet needs in oncology care.
Jurgen Van Broeck brings experience and a proven track record in the pharmaceutical and biosimilar industries.
Signals a step in mAbxience's global expansion strategy and advances Teva’s goal to expand its biosimilar pipeline through business development.
Serves as a generic substitute for Cytoxan, for use in treating several forms of cancer.
mAbxience will manufacture the active ingredient Agalsidase Beta, developed by Biosidus as a biosimilar of Fabrazyme for the treatment of Fabry disease.
Invests nearly $1 billion to double U.S. manufacturing capacity and enhance production and distribution network.
Companies are looking to diversify their API suppliers and manufacturers to different locations instead of outsourcing it to just one manufacturer.
By: Grandview Research
Expands global presence and adds significant capacity for sterile liquid manufacturing.
By: Anthony Vecchione
Aims to help lessen the manufacturing barriers for cell and gene therapies by integrating cutting-edge automation tools.
Enter the destination URL
Or link to existing content
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
